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t(11;14)(q13;q32) G-banding (left) - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at the Waisman 
Center and R-banding (right) - Editor. 
Note: t(11;14) is mainly found in mantle cell 
lymphoma, but also in B-prolymphocytic leukaemia, in 
plasma cell leukaemia, in splenic lymphoma with 
villous lymphocytes, in chronic lymphocytic 
leukaemia, and in multiple myeloma, herein briefly 
described; all these diseases involve a B-lineage 
lymphocyte 
Clinics and pathology 
Disease 
Mantle cell lymphoma. 
Phenotype / cell stem origin 
B-cell non Hodgkin lymphoma of the low to 
intermediate grade. 
Epidemiology 




Median survival: 3 to 4 yrs. 
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Disease 
B-prolymphocytic leukaemia. 
Phenotype / cell stem origin 
Chronic lymphoproliferative disorder affecting mature 
B-cells. 
Epidemiology 
Rare disease; median age 70 yrs. 
Clinics 
Patients often present with advanced stage disease. 
Prognosis 
Median survival: 3 yrs. 
Disease 
Plasma cell leukaemia. 
Phenotype / cell stem origin 




Median survival is less than a yr. 
Disease 
Splenic lymphoma with villous lymphocytes. 
Phenotype / cell stem origin 
Chronic B-cell lymphoproliferation. 
Epidemiology 
Rare disorder; median age: 70 yrs. 
Clinics 
Relatively benign clinical course. 
Prognosis 
80% 5-yr survival. 
Disease 
Chronic lymphocytic leukaemia. 
Phenotype / cell stem origin 
Chronic B-cell lymphoproliferation. 
Epidemiology 
Annual incidence 30/106; median age: 60-80 yrs. 
Clinics 
Often a slow evolutive disease. 
Prognosis 
Highly variable according to the staging: from staging 
A: survival not reduced compared to age matched 
population, to staging C: median survival of 2 yrs. 
Disease 
Multiple myeloma. 
Phenotype / cell stem origin 
Malignant plasma cell proliferation (terminally 
differentiated B-cell). 
Epidemiology 
Annual incidence: 30/106; median age: 60 yrs. 
Prognosis 
Median survival: 3 yrs. 
Cytogenetics 
Cytogenetics, morphological 
t(11;14) has earlier been thought to be the hallmark of 
the mantle cell lymphoma; actually, the frequency of 
t(11;14) is: 50-70% in mantle cell lymphoma, 10-20% 
in B-prolymphocytic leukaemia, in plasma cell 
leukaemia, and in splenic lymphoma with villous 
lymphocytes, and 2-5% in chronic lymphocytic 
leukaemia, and in multiple myeloma. 
Cytogenetics, molecular 
In particular interphase cytogenetics, are relevant in 
these diseases with an usually low mitotic index. 
Additional anomalies 
Sole anomaly in only 10% of cases; part of a complex 
karyotype in 2/3 of cases; numerous recurrent 
anomalies found conjointly (which is the primary?), 
particularly: +3, +7, del(9p), +18, +mar, found in about 
10% of cases each; other: del(1p), del(6q), del(7q), -8, 
+12, del(13q), del(17p). 
Variants 
Three way complex t(11;14;Var) exist and showed that 
the crucial event lies on der(14). 
Genes involved and Proteins 
BCL1 
Location: 11q13 
DNA / RNA 
5 exons. 
Protein 
Encodes the cyclin D1; role in the cell cycle contrl: 
G1 progression and G1/S transition. 
IgH 
Location: 14q32 




5' BCL1 translocated on chromosome 14 near JH 
(junctions genes of IgH) and C in 3'; the breakpoint in 
BCL1 is in MTC (major translocation cluster), 
centromeric to the gene (in 5'), in 80% of cases, or 
dispersed in mTC1, 2, or 3 in 5' of the gene or in the 3' 
untranslated region of exon 5. 
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Fusion protein 
Description 
No fusion protein, but promoter exchange; the 
immunoglobulin gene enhancer stimulates the 
expression of BCL1. 
Oncogenesis 
Overexpression of BCL1 accelerates passage through 
the G1 phase. 
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